AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
== Effects == Lean produces mild-to-moderate "euphoric side effects" accompanied by "motor-skill impairment, lethargy, drowsiness, and a dissociative feeling from all other parts of the body." It has been suggested that the super-sweet combination of soda, cough syrup, and Jolly Ranchers provides a pleasing flavor and mouthfeel that lingers on the user's tongue for an extended duration. This phenomenon is often appealing to first-time users. Lean is often used in combination with alcohol, smoked cannabis or other recreational drugs.
=== Banlieue Triste (2018–2020) === Hangman's Chair's fifth album, Banlieue Triste (lit. 'Sad Suburb'), was released in March 2018 through Music Fear Satan. The album features two guest contributions: one from Marc De Backer of Mucky Pup on "Sidi Bel Abbes", and the other from French synthwave musician Perturbator on "Tired Eyes". Banlieue Triste spawned a music video for "Naive" released in April 2018, starring French actor Nicolas Duvauchelle. Duvauchelle, who was part of the Parisian hardcore scene with his band Cry Havoc and is a longtime friend of Hangman's Chair, stated: "I didn't hesitate for a second. They're such a negative band, and I love it". He played his part as a volunteer. In May, a music video for "Touch the Razor", produced by 12jours (lit. '12days'), was released on Vimeo. On 15 June, they performed at Download Festival France at the Brétigny-sur-Orge Air Base 217.
=== Journalist spying scandal === In October 2022, Forbes reported that a team at ByteDance planned to surveil certain US citizens for undisclosed reasons. TikTok said that the tracking method suggested by the report would not be feasible because precise GPS information is not collected by the platform. In December 2022, ByteDance confirmed after internal investigation that the data of two journalists and their close contacts had been accessed by its employees from China and the United States. It was intended to uncover sources of leaks who might have met with the journalists from Forbes and the Financial Times. The data included IP addresses, which can be used to approximate a user's location. ByteDance stated that it fired four employees in response. The incident is being investigated by the US Department of Justice and FBI. The US Attorney for the Eastern District of Virginia reportedly subpoenaed information from ByteDance regarding its surveillance of journalists on TikTok. In December 2023, the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party inquired the FBI about the status of the case.
Sources: en.wikipedia.org
It has also been linked to the production of RNA-edited proteins that are incorporated into the polypeptide complexes of the respiration pathway. Therefore, it is highly probable that polypeptides synthesized from unedited RNAs would not function properly and hinder the activity of both mitochondria and plastids. C-to-U RNA editing can create start and stop codons, but it cannot destroy existing start and stop codons. A cryptic start codon is created when the codon ACG is edited to be AUG.
Along with Mastodon and Deftones, Alice in Chains toured the United States and Canada in late 2010 on the Blackdiamondskye tour, an amalgam of the three bands' latest album titles (Black Gives Way to Blue, Diamond Eyes, and Crack the Skye). On March 8, 2011, former Alice in Chains bassist Mike Starr was found dead at his home in Salt Lake City. Police told Reuters they were called to Starr's home at 1:42 pm and found his body; Starr was 44. Reports later surfaced that Starr's roommate had seen him mixing methadone and anxiety medication hours before he was found dead. Later reports indicated Starr's death may have been linked to two different types of antidepressants prescribed to him by his doctor. A public memorial was held for Starr at the Seattle Center's International Fountain on March 20, 2011. A private memorial was also held, which Jerry Cantrell and Sean Kinney attended according to Mike Inez.
=== 2000–2006 === The years from 2000 to 2006 were bloody ones in Colombia with thousands of deaths every year resulting from the ongoing war between the Colombian Armed Forces, Paramilitary groups such as the AUC, and the rebel groups (mainly the FARC, ELN and the EPL). The fighting resulted in massive internal displacement of Colombia's civilian population and thousands of civilian deaths. During President Uribe's first term in office (2002–2006), the security situation inside Colombia showed some measure of improvement, and the economy, while still fragile, showed some positive signs of recovery, according to observers. However, relatively little had been accomplished in structurally solving the country's other grave problems, such as poverty and inequality, possibly in part due to legislative and political conflicts between the administration and the Colombian Congress (including those over a controversial project to eventually give Uribe the possibility of re-election) and a relative lack of freely allocated funds and credits. Some critical observers considered that Uribe's policies, while reducing crime and guerrilla activity, were too slanted in favor of a military solution to Colombia's internal war, while neglecting grave social and human rights concerns. Critics asked for Uribe's government to change this position and make serious efforts towards improving the human rights situation inside the country, protecting civilians, and reducing any abuses committed by the armed forces.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.